Radiotherapy/Radiation / eff Cancer Research Results

Rad, Radiotherapy/Radiation: Click to Expand ⟱
Features:
Treatment of disease with radiation, especially by selective irradiation with x-rays or other ionizing radiation and by ingestion of radioisotopes.

Radiosensitizer
Atorvaqone, (mitochondria inhibitor) decrease O2 consumption making more O2 available as a radiosensitizer.
eff, efficacy: Click to Expand ⟱
Source:
Type:
Power to enhance an anti cancer effect
Scientific Papers found: Click to Expand⟱
2063- PB,  Rad,    Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation
- in-vitro, GBM, U87MG - NA, NA, U251
RadioS↑, eff↝, P53↝,
5079- SSE,  Rad,    The solvent and treatment regimen of sodium selenite cause its effects to vary on the radiation response of human bronchial cells from tumour and normal tissues
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B
chemoP↑, eff↝, ROS↑, MMP↓, Cyt‑c↑, TumCG↓, RadioS↝, other↝,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Cell Death ⓘ

Cyt‑c↑, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

DNA Damage & Repair ⓘ

P53↝, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↝, 2,   RadioS↑, 1,   RadioS↝, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: eff, efficacy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:201  Target#:961  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page